Results 81 to 90 of about 37,111 (253)

Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR‐Mutated Locally Advanced or Metastatic Lung Cancer

open access: yesInternational Journal of Cancer, EarlyView.
Non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations often exhibit significant tumor reduction following tyrosine kinase inhibitor (TKI) therapy. Residual tumors frequently remain, however, leading to drug resistance and disease progression.
Fedor Moiseenko   +31 more
wiley   +1 more source

Two contrasting cases of adrenal insufficiency in adults: a case report

open access: yesJournal of Medical Case Reports
Background Adrenal insufficiency (AI) is a clinical syndrome characterized by insufficient secretion of glucocorticoids and/or mineralocorticoids.
Yingqi Guo
doaj   +1 more source

When It’s Not Just Hypothyroidism

open access: yesGraduate Medical Education Research Journal, 2019
Mentor: Whitney S Goldner Program: Diabetes, Endocrinology, and Metabolism Background: Autoimmune Polyglandular Type II Syndrome is characterized by Autoimmune Thyroid disease, Type1 Diabetes, and Primary Adrenal Insufficiency.
Preethi Polavarapu, Whitney S Goldner
doaj   +1 more source

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT‐OES‐1 Trial

open access: yesInternational Journal of Cancer, EarlyView.
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
Charlène J. van der Zijden   +12 more
wiley   +1 more source

Bilateral adrenal hemorrhage in a postpartum woman with multiple thromboemboli: A case report

open access: yesJournal of Medical Case Reports
Background Bilateral adrenal hemorrhage is a rare but often a fatal cause of primary adrenal insufficiency that can result in adrenal crisis if not identified and managed appropriately.
Anna Yi Nan Jiang   +7 more
doaj   +1 more source

Primary adrenal insufficiency

open access: yes, 2021
Primary adrenal insufficiency is a rare condition caused by pathology of the adrenal gland itself, often due to autoimmune adrenalitis or inborn error of steroidogenesis. The adrenal cortex contains three zones, and each zone produces a different hormone - the zona glomerulosa (aldosterone), the zona fasciculata (cortisol), and the zona reticularis ...
openaire   +1 more source

Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Somatostatin receptors (SSTR) mediate the antiproliferative, antisecretory, and proapoptotic effects of somatostatin and its synthetic analogs. Their surface expression on neuroendocrine tumor (NET) cells is required for somatostatin analog therapy and radiopharmaceutical therapy (RPT).
Neeraj Kumari   +10 more
wiley   +1 more source

Delay in Diagnosis of Adrenal Insufficiency Is a Frequent Cause of Adrenal Crisis

open access: yesInternational Journal of Endocrinology, 2013
Delay of diagnosis of primary adrenal insufficiency (PAI) leads to adrenal crisis which is potentially lethal complication. The objective of our work was an assessment whether the establishment of diagnosis of adrenocortical insufficiency in Poland is ...
Lucyna Papierska, Michał Rabijewski
doaj   +1 more source

Glucocorticoid deficiency causes transcriptional and post-transcriptional reprogramming of glutamine metabolismResearch in context section

open access: yesEBioMedicine, 2018
Background: Deficient glucocorticoid biosynthesis leading to adrenal insufficiency is life-threatening and is associated with significant co-morbidities.
Meltem Weger   +11 more
doaj   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy